It's easier to invest confidently when you know both the pros and the cons in full. Summit Therapeutics (SMMT 7.20%) is an exciting stock for many investors as its shares are up by 158% in the last three months alone. But, as wise investors know, recent price action is in no way a substitute for doing due diligence. And, given that this company doesn't yet have any revenue, the need to do some research and cover your bases is especially important. So with the spirit of delving a bit deeper in mind, let's lo ...

The investment bank analysts who follow these stocks think they can soar even further, with some caveats. Shares of Viking Therapeutics (VKTX 1.33%) and Summit Therapeutics (SMMT 2.58%) are crushing the market this year. Prices for both stocks have more than tripled in 2024 thanks to positive news flow for Viking's oral weight loss candidate and surprising results for Summit's cancer therapy hopeful. What goes up often comes down, but the investment bankers who follow these stocks expect further gains. Oppe ...

This company's promising cancer drug could challenge Merck's $25 billion crown jewel. The pharmaceutical industry is often about hitting home runs. Big pharmaceutical companies start small, and then a blockbuster product catapults them into the spotlight. Summit Therapeutics (SMMT 2.58%) has soared 1,000% over the past year on progress in developing a drug that could rival Merck's Keytruda, a product used to treat various cancers with over $25 billion in sales last year. Those who got in early have gotten r ...

Recent developments are forcing comparisons between these two drugmakers. Many pharmaceutical and biotech companies have one or a few main areas of expertise in which they develop and market their most important medicines. For Merck (MRK -1.70%), one of the most prominent companies in the business, that area is oncology. Merck is best known for its cancer drug Keytruda, which has been the best-selling medicine in the world since last year. It has several other cancer drugs in its portfolio although their sa ...

There's a lot riding on how its collaborator's studies end up performing. Believe it or not, it's entirely possible to build out a successful biopharma without actually doing much (or any) work in the laboratory. And, at least for now, that's exactly what Summit Therapeutics (SMMT -2.79%) is angling to do. Thanks to its collaboration with a highly capable company abroad, this biotech may soon demonstrate the powerful financial performance that's possible using an asset-light business model. With that frame ...

Summit Therapeutics stock is up a remarkable 700% this year. When a stock gets red hot, its share price can sometimes soar to unsustainable levels as euphoria ends up taking over. One of the hottest stocks to own this year has undoubtedly been Summit Therapeutics (SMMT -8.22%), and it could very well fall into that category. Even though the promising biotech doesn't have an approved product in its portfolio and is generating no revenue, the excitement around one of its oncology treatments has investors incr ...

Its alliance with a successful foreign biotech could be decisive for the stock. Summit Therapeutics' (SMMT -8.44%) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the company and its main collaborator. Now the question is whether Summit can continue wowing investors as its candidates approach their shot at commercialization. But you might look at its pipeline and conclude that the biotech is a one-trick ...

One of them is performing much better than the other this year. The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics (VKTX -1.11%) and Summit Therapeutics (SMMT -8.44%), two clinical-stage drugmakers, have seen their shares skyrocket. The reason? Both companies announced promising clinical progress for their leading pipeline candidates. While there's still some way to go before launching their products, it's hard to argue with the result ...

These relatively small companies are developing new cancer therapies that could generate billions in annual sales. Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares of Summit Therapeutics and Instil Bio marched over 700% higher. These stocks have outperformed because the new drug candidates they're developing could become some of the most successful cancer trea ...

How long will the momentum last? Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue to grow incredibly fast. Nvidia's shares are up by 137% this year. Some companies have performed even better, including one many investors may never have heard about: Summit Therapeutics (SMMT 5.31%). The biotech's performance this year makes Nvidia's look mediocre: Summit's shar ...